Microvascular complications - DiabetesontheNet

This site is intended for healthcare professionals only

Microvascular complications

Filter:

How to use SGLT2 inhibitors safely and effectively

Using sodium–glucose cotransporter 2 inhibitors safely, effectively and in line with the latest NICE guidance

18 Sep 2023

At a glance factsheet: Diabetic gastroparesis

What causes gastroparesis and what is primary care’s role in managing it?

18 Sep 2023

Q&A: Diabetic retinopathy

Retinopathy pathophysiology, screening and treatment: The experts answer key questions.

20 Jul 2023

Interactive case study: Erectile dysfunction in type 2 diabetes

The causes and management of erectile dysfunction in men with type 2 diabetes.

20 Jul 2023

Diabetes Distilled: Lifestyle change for microvascular gain

Five healthy behaviours to reduce microvascular complications in people with type 2 diabetes.

20 Jul 2023

Diabetes Distilled: Renoprotective benefits associated with SGLT2 inhibitor use in real-world studies

Meta-analysis suggests SGLT2 inhibitors are associated with a 46% lower risk of renal failure compared with other diabetes drugs.

20 Jul 2023

Network meta-analysis of benefits and harms associated with currently available type 2 diabetes drugs

Monumental analysis synthesises current evidence on the benefits and risks associated with currently available diabetes drug classes.

23 Jun 2023

Real-world data demonstrate renoprotective effects of SGLT2 inhibitors

Renoprotective benefits of SGLT2 inhibitors extend to the broader population of people with type 2 diabetes who are treated in routine clinical practice.

23 Jun 2023

Need to know guide: Pharmacological treatment of painful neuropathy in adults with diabetes

A printable guide with prescribing guidance on analgesic drugs for painful diabetic neuropathy.

10 May 2023

You are what – and when – you eat

New evidence on low-carb diets, ultra-processed foods and time-restricted eating, plus GLP-1 RAs, risk markers and diabetes complications.

24 Mar 2023

Cardiorenal effects of improving multiple risk factors

Improvements in multiple risk markers are associated with a lower risk of cardiovascular and kidney outcomes.

24 Mar 2023

The 2023 ADA Standards of Care: What’s new?

Key changes that were published in January 2023, with comparisons to UK guidelines.

23 Feb 2023

Diabetes Distilled: More evidence that SGLT2 inhibitors slow CKD progression. Are we optimising care?

Empagliflozin's renoprotective effects extend to people with eGFR levels as low as 20 at baseline.

23 Feb 2023

Journal club: Ideas for improving patient outcomes – the quirky and the ones in the guidelines

Discussion of recent notable papers. Simple changes that could be made to improve outcomes of people with type 2 diabetes.

3 Jan 2023

Type 1 diabetes prevention and screening, hybrid closed-loop systems, principles of good peer support

Stay abreast of the latest news that could impact diabetes nursing.

3 Jan 2023

Cardiovascular and renal outcomes of glucose-lowering drugs: Updated meta-analysis

Data from 260 trials of eight drug classes highlights the benefits of metformin, SGLT2 inhibitors, GLP-1 RAs and pioglitazone.

11 Dec 2022

EMPA-KIDNEY trial shows benefits of empagliflozin in CKD

Reduced risk of renal progression and cardiovascular death in a wide range of people with CKD, with eGFR as low as 20.

18 Nov 2022

At a glance factsheet: Diabetes-related sensory peripheral neuropathy

The basics of diabetic neuropathy, including pathophysiology, screening and pain management.

30 Oct 2022

Resources

For the latest news and articles

Resources

Journals

Useful information

;

Clear